Pharmaceutical giants eye tiny startup company for drug that could beat cancer
Tiny Immunocore of England harnesses T-cells to battle tumors
Two international pharmaceutical giants have their eyes set on a tiny, unassuming British startup company called Immunocore. Housed in a nondescript, single-story business park in Oxfordshire, Immunocore has found a way to use the mighty T-cell to fight tumors, paving the way for a possible cure for cancer.
Dr. Bent Jakobsen began the study T-cells 20 years ago while working at the Medical Research Council's Laboratory of Molecular Biology in Cambridge.
It's possible that Immunocore is the only company in the world that has developed a way of harnessing the power of the immune system's natural-born killer cells. T-cells found in the blood cells of humans, designed over millions of years of evolution to seek out and kill invading pathogens.
Executives of the drugs industry, known for their caution in funding research believes that Immunocore may have found a detour in order for future cancer patients are able to fend off their disease with their own immune defenses.
The former academics who set up Immunocore have worked hard on realizing their dream of developing a totally new approach to cancer treatment - and it is beginning to look as if it will finally pay off. "Immunotherapy is radically different," Bent Jakobsen, the Danish-born chief scientific officer of Immunocore says. Jakobsen began the study T-cells 20 years ago while working at the Medical Research Council's Laboratory of Molecular Biology in Cambridge.
"It doesn't do away with the other cancer treatments by any means, but it adds something to the arsenal that has one unique feature - it may have the potency to actually cure cancer," Jakobsen says.
Jakobsen and his colleague's research has piqued the interest of both Genentech in California, owned by the Swiss giant Roche, and Britain's GlaxoSmithKline. Both companies have signed deals with Immunocore that could result in up to half a billion pounds being invested in new cancer treatments based on its unique T-cell therapy.
Cancer immunotherapy, or immuno-oncology as it is technically called, represents a sea change in terms of cancer treatment. Cancer in the past has been largely treated by "slicing," via surgery, "poisoning" via chemotherapy or "burning" via radiotherapy. All three methods are burdened with the inherent problem of how to spare healthy tissue from irreparable damage while ensuring that every cancer cell is killed, deactivated or removed.
The new approach, based on the immune system, a complex web of cells, tissues and organs that constantly strive to keep the body free of disease, which almost certainly includes keeping cancerous cells in check.
Scientists have known for years that the immune system plays a key role in cancer prevention. There is ample evidence of this, not least from patients who are immune-suppressed in some way - they are more likely than other patients to develop cancer.
Many organizations have tried to develop anti-cancer treatments based on antibodies, with limited success, Jakobsen said. Part of the problem is that antibodies are not really designed to recognize cells. Immunocore has built a therapy around the second arm of the immune system, known as cellular immunity, where T-cells seek out and destroy invading pathogens.
"There are a lot of companies working with antibodies but we are virtually the only company in the world that has managed to work with T-cells. It has taken 20 years and from that point we are unique," Jakobsen says.
© 2013, Distributed by NEWS CONSORTIUM.
Pope Francis Prayer Intentions for December 2013
General Intention: Victimized Children. That children who are victims of abandonment or violence may find the love and protection they need.
Missionary Intention: Prepare the Savior's Coming. That Christians, enlightened by the Word incarnate, may prepare humanity for the Savior's coming.
Rate This Article
Leave a Comment
More Health News
- Donors from around the world say that an AIDS-free generation may be within sight
- Washington signing up more people for Medicaid than private plans
- Man documents ravages of diabetes to his feet as they decay within 10 DAYS
- Dementia epidemic only growing worse: 135 million sufferers could arrive by 2050
- Men are from Mars, Women from Venus? Their brains are certainly wired differently
- Drinking water from plastic cups, bottles may be causing migraine headaches
- Apocalypse imminent as bacteria evolve beyond antibiotics
- New injection gives arthritics new hope
- Overweight people need to curb blood pressure to cut heart attack risk, doctors say
- Fr. Paul Schenck: Finding Living Faith on Catechetical Sunday
- The Movie Yellow: Incest as 'Normal' and Cassavates's Slides Into the World of Woes
- The Chicago School Teachers Strike Reveals the Need For School Choice
- The Sexual Barbarians and the Dissolution of Culture
- The Happy Priest Challenges Us to Ask: Who is Jesus to Me?
- Michael Coren on Canadian Public Schools: Teachers, leave those kids alone
- We Cannot Ignore Our Consciences: Cardinal Dolan On Religious Liberty
- In the Face of Danger, Successor of Peter Travels to Lebanon as a Messenger of Peace
- Reflections on the Dignity and Vocation of Women: Who or What?